Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients (PACIFIC-4)

Active Date: June 12, 2019

IRB Number: PACIFIC-4

Condition/Disease: Lung Cancer

Lead Researcher: Brian Myre, MD

Location: Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield
Nancy Knowles Cancer Center - Elmhurst

Purpose:

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab versus placebo following SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.

Sponsor: AstraZeneca

https://clinicaltrials.gov/ct2/show/NCT03833154

Eligibility:

Stage I to II NSCLC, lymph node-negative (T1 to T3N0M0)
Completion of SoC SBRT as definitive treatment prior to randomization
Life expectancy of at least 12 weeks
Body weight >30 kg
Patients with central or peripheral lesions are eligible
No mixed small cell and non-small cell cancer histology

Time Commitment:

6 years

Status: Accepting Participants

Current Trial Type: Interventional

Phase: III

Contact Name: Jessica Schnase, Mgr Cancer Research

Phone: 630-646-6072

Fax: 630-646-6074

Alternate Phone: 630-646-6073